Breaking News

Redx Pharma Launches R&D Division at AZ Site

Will focus on drug resistant bacteria and viral infections

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Redx Pharma is opening a new R&D facility at AstraZeneca’s Alderley Park site in Cheshire, UK. The new venture, Redx Anti-Infectives Ltd., will employ a team of 119 scientists to develop drugs combating resistance to antibiotics and new medicines for viral infections. These include the threat of superbugs like MRSA, as well as influenza, hepatitis C and HIV. Redx Anti-Infectives is the third business created by the Redx Pharma group, which includes Redx Oncology and Redx Crop Protection.   D...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters